Observed frequency and challenges of variant reclassification in a hereditary cancer clinic

Sarah Macklin, Nisha Durand, Paldeep Atwal, Stephanie Hines

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: Efforts have been made by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology to make variant classification more uniform, but many limitations remain. Reclassification of a variant of uncertain significance (VUS) is expected, but other more certain calls, like pathogenic or benign, can also be reclassified once additional information is gathered. Variant reclassification can create difficult circumstances for both patients and clinicians. Methods: Retrospective review of all variant reclassifications in genes associated with hereditary cancer syndromes at one clinic between September 2013 and February 2017 was completed. All variant reclassifications were completed and reported by the original testing laboratory. Results: A total of 1,103 hereditary cancer tests were ordered. Fewer than 5% (40/1,103) of the initial reports were updated during that time period. Most reclassifications (29/40) were downgrades of VUS to likely benign. Only three reclassifications could potentially alter medical management. Conclusion: The majority of variant reclassifications do not impact medical management. Upgrading a variant call to pathogenic could be important for a patient's care and shows the importance of open communication between laboratories and clinicians. A variant downgrade from pathogenic can be a significant reclassification as well, especially if prophylactic surgery has been completed.

Original languageEnglish (US)
Pages (from-to)346-350
Number of pages5
JournalGenetics in Medicine
Volume20
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Hereditary Neoplastic Syndromes
Molecular Pathology
Genomics
Neoplasms
Patient Care
Communication
Genes

Keywords

  • hereditary cancer clinic
  • hereditary cancer syndrome
  • variant classification
  • variant of uncertain significance
  • variant reclassification

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Observed frequency and challenges of variant reclassification in a hereditary cancer clinic. / Macklin, Sarah; Durand, Nisha; Atwal, Paldeep; Hines, Stephanie.

In: Genetics in Medicine, Vol. 20, No. 3, 01.03.2018, p. 346-350.

Research output: Contribution to journalArticle

Macklin, Sarah ; Durand, Nisha ; Atwal, Paldeep ; Hines, Stephanie. / Observed frequency and challenges of variant reclassification in a hereditary cancer clinic. In: Genetics in Medicine. 2018 ; Vol. 20, No. 3. pp. 346-350.
@article{e8e40384db0d44e684cf8d6ffb6b0422,
title = "Observed frequency and challenges of variant reclassification in a hereditary cancer clinic",
abstract = "Purpose: Efforts have been made by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology to make variant classification more uniform, but many limitations remain. Reclassification of a variant of uncertain significance (VUS) is expected, but other more certain calls, like pathogenic or benign, can also be reclassified once additional information is gathered. Variant reclassification can create difficult circumstances for both patients and clinicians. Methods: Retrospective review of all variant reclassifications in genes associated with hereditary cancer syndromes at one clinic between September 2013 and February 2017 was completed. All variant reclassifications were completed and reported by the original testing laboratory. Results: A total of 1,103 hereditary cancer tests were ordered. Fewer than 5{\%} (40/1,103) of the initial reports were updated during that time period. Most reclassifications (29/40) were downgrades of VUS to likely benign. Only three reclassifications could potentially alter medical management. Conclusion: The majority of variant reclassifications do not impact medical management. Upgrading a variant call to pathogenic could be important for a patient's care and shows the importance of open communication between laboratories and clinicians. A variant downgrade from pathogenic can be a significant reclassification as well, especially if prophylactic surgery has been completed.",
keywords = "hereditary cancer clinic, hereditary cancer syndrome, variant classification, variant of uncertain significance, variant reclassification",
author = "Sarah Macklin and Nisha Durand and Paldeep Atwal and Stephanie Hines",
year = "2018",
month = "3",
day = "1",
doi = "10.1038/gim.2017.207",
language = "English (US)",
volume = "20",
pages = "346--350",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Observed frequency and challenges of variant reclassification in a hereditary cancer clinic

AU - Macklin, Sarah

AU - Durand, Nisha

AU - Atwal, Paldeep

AU - Hines, Stephanie

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Purpose: Efforts have been made by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology to make variant classification more uniform, but many limitations remain. Reclassification of a variant of uncertain significance (VUS) is expected, but other more certain calls, like pathogenic or benign, can also be reclassified once additional information is gathered. Variant reclassification can create difficult circumstances for both patients and clinicians. Methods: Retrospective review of all variant reclassifications in genes associated with hereditary cancer syndromes at one clinic between September 2013 and February 2017 was completed. All variant reclassifications were completed and reported by the original testing laboratory. Results: A total of 1,103 hereditary cancer tests were ordered. Fewer than 5% (40/1,103) of the initial reports were updated during that time period. Most reclassifications (29/40) were downgrades of VUS to likely benign. Only three reclassifications could potentially alter medical management. Conclusion: The majority of variant reclassifications do not impact medical management. Upgrading a variant call to pathogenic could be important for a patient's care and shows the importance of open communication between laboratories and clinicians. A variant downgrade from pathogenic can be a significant reclassification as well, especially if prophylactic surgery has been completed.

AB - Purpose: Efforts have been made by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology to make variant classification more uniform, but many limitations remain. Reclassification of a variant of uncertain significance (VUS) is expected, but other more certain calls, like pathogenic or benign, can also be reclassified once additional information is gathered. Variant reclassification can create difficult circumstances for both patients and clinicians. Methods: Retrospective review of all variant reclassifications in genes associated with hereditary cancer syndromes at one clinic between September 2013 and February 2017 was completed. All variant reclassifications were completed and reported by the original testing laboratory. Results: A total of 1,103 hereditary cancer tests were ordered. Fewer than 5% (40/1,103) of the initial reports were updated during that time period. Most reclassifications (29/40) were downgrades of VUS to likely benign. Only three reclassifications could potentially alter medical management. Conclusion: The majority of variant reclassifications do not impact medical management. Upgrading a variant call to pathogenic could be important for a patient's care and shows the importance of open communication between laboratories and clinicians. A variant downgrade from pathogenic can be a significant reclassification as well, especially if prophylactic surgery has been completed.

KW - hereditary cancer clinic

KW - hereditary cancer syndrome

KW - variant classification

KW - variant of uncertain significance

KW - variant reclassification

UR - http://www.scopus.com/inward/record.url?scp=85044618205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044618205&partnerID=8YFLogxK

U2 - 10.1038/gim.2017.207

DO - 10.1038/gim.2017.207

M3 - Article

AN - SCOPUS:85044618205

VL - 20

SP - 346

EP - 350

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 3

ER -